 |
|
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Korean J Intern Med. 2018;33(6):1224-1233. Published online 2018 Jan 5 DOI: https://doi.org/10.3904/kjim.2016.213
|
|
Citations to this article as recorded by
 Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment
Yan Luo, Konstantina Chalkou, Satoshi Funada, Georgia Salanti, Toshi A. Furukawa
JAMA Network Open.2023; 6(6): e2321398. CrossRef Comparative Efficacy of bDMARDs and tsDMARDs for the Treatment of Rheumatoid arthritis: A Systematic Review and Network Meta-Analysis
Penghua Shi, Li Wang, Jiafang He, Yun Lu
International Journal of Biology and Life Sciences.2023; 3(1): 35. CrossRef The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis
Bei He, Yun Li, Wen-wen Luo, Xuan Cheng, Huai-rong Xiang, Qi-zhi Zhang, Jie He, Wen-xing Peng
Frontiers in Immunology.2022;[Epub] CrossRef Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection
S. Jayashree, K. Nirekshana, Gunjan Guha, Dipita Bhakta-Guha
Biomedicine & Pharmacotherapy.2018; 102: 894. CrossRef
|